Analyst Price Target is $25.71
▲ +262.17% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is $25.71, with a high forecast of $33.00 and a low forecast of $15.00. The average price target represents a 262.17% upside from the last price of $7.10.
Current Consensus is
Buy
The current consensus among 9 contributing investment analysts is to buy stock in EyePoint Pharmaceuticals. This Buy consensus rating has held steady for over two years.
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Read More
